Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FSHR | P23945 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077188 | 0.87 | KMT2A (0.59) | KMT2ANAMPTSMN1; SMN2RAB9AFSHR | |
| SCHEMBL4488063 | 0.84 | NAMPT (0.63) | KMT2AALDH1A1TSHRNAMPTSMN1; SMN2 | |
| SCHEMBL6076304 | 0.80 | HDAC1 (0.50) | NAMPTHDAC1 | |
| SCHEMBL6385896 | 0.77 | L3MBTL1 (0.60) | KMT2AALDH1A1TSHRNAMPTSMN1; SMN2 | |
| SCHEMBL6076395 | 0.76 | HDAC1 (0.50) | TSHRNAMPTHDAC1 | |
| SCHEMBL212371 | 0.72 | HDAC1 (0.56) | HDAC1 | |
| SCHEMBL16495441 | 0.71 | TSHR (0.66) | KMT2AALDH1A1TSHRNAMPTSMN1; SMN2 | |
| SCHEMBL6076286 | 0.71 | HPGD (0.55) | RAB9AHDAC1 | |
| SCHEMBL11479783 | 0.70 | KMT2A (0.67) | KMT2AALDH1A1TSHRSMN1; SMN2RAB9A | |
| SCHEMBL4233224 | 0.70 | KMT2A (0.45) | KMT2AALDH1A1TSHRSMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | claimed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | claimed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | claimed |
| US-7098247-B2 | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | MKI67, API5, ACIN1 | KMT2A 3744/4885ALDH1A1 95/4885TSHR 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.